Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study,

Cristina Skert, MD, Manuela Fogli, Simone Perucca, Simona Fiorentini, Emirena Garrafa, Jr., Carla Filì, Annalisa Peli, MD, Chiara Colombi, Cesare Bergonzi, Michele Malagola, Alessandro Turra, Arnaldo Caruso, Domenico Russo

Blood (2011) 118 (21): 4071.

https://doi.org/10.1182/blood.V118.21.4071.4071

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation

Cristina Skert, MD, Manuela Fogli, Simone Perucca, Simona Fiorentini, Emirena Garrafa, Jr., Carla Filì, Chiara Colombi, Annalisa Peli, MD, Cesare Bergonzi, Michele Malagola, Elisa Alghisi, Alessandro Turra, Arnaldo Caruso, Domenico Russo

Blood (2011) 118 (21): 4924.

https://doi.org/10.1182/blood.V118.21.4924.4924

Published: 2011

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Blood (2010) 116 (21): 4029.

https://doi.org/10.1182/blood.V116.21.4029.4029

Published: 2010

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

Blood (2009) 114 (22): 4851.

https://doi.org/10.1182/blood.V114.22.4851.4851

Published: 2009

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

Journal Articles

Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy

Domenico Russo, Michele Malagola, Chiara Colombi, Massimo Breccia, Miriam Fogli, Piero Galieni, Giovanni Martinelli, Salvatore Mirto, Umberto Vitolo, Elisabetta Abruzzese, Giuliana Alimena, Monica Bocchia, Angelo Michele Carella, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Giorgina Specchia, Michele Baccarani

Blood (2008) 112 (11): 4288.

https://doi.org/10.1182/blood.V112.11.4288.4288

Published: 2008

NARROW

Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study,

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only